If you could vote on Brexit now which option would you choose?
   

AstraZeneca sells another half-million doses of its COVID-19 antibody combo to the US


Order up. Shortly after topping off supplies of COVID-19 drugs from Pfizer and GlaxoSmithKline, the U.S. has asked for a second helping of AstraZeneca’s antibody combo. The government has purchased an additional 500,000 doses of AZ’s long-acting antibody cocktail Evusheld, or tixagevimab plus cilgavimab. That comes on top of 700,000 doses the U.S. already ordered, for a total supply of 1.2 million, the British drugmaker said Wednesday. AstraZeneca plans to complete the entire delivery within the first quarter of 2022. Unlike the COVID-19 antibody drugs from Eli Lilly, Regeneron and GlaxoSmithKline-Vir Biotechnology, AstraZeneca’s therapeutic is authorized for prevention before exposure to the virus. Specifically, the FDA in December authorized Evusheld in people with moderately to severely compromised immune systems, either from a medical condition or the use of immunosuppressive medications. People with a history of severe reactions to COVID-19 vaccines are also eligible to receive the therapeutic.

FiercePharma - January 12, 2022

View the full story here: https://www.fiercepharma.com/pharma/astrazeneca-sells-half-a-million-more-doses-its-covid-19-antibody-combo-u-s